Subsequent Events (Details) - Subsequent Event - Cumberland Pharmaceuticals Inc. - Apotex |
Apr. 22, 2026
USD ($)
|
|---|---|
| Subsequent Event [Line Items] | |
| Asset acquisition, price of acquisition, expected | $ 100,000,000 |
| Asset acquisition, monthly receivable, amount | 150,000 |
| Asset acquisition, reimbursement receivable, amount | $ 9,000,000 |
| X | ||||||||||
- Definition Asset Acquisition, Monthly Receivable, Amount No definition available.
|
| X | ||||||||||
- Definition Asset Acquisition, Reimbursement Receivable, Amount No definition available.
|
| X | ||||||||||
- Definition Purchase price of expected asset acquisition prior to consideration being transferred. Excludes business acquisition. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|